<DOC>
	<DOCNO>NCT00054106</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Drugs flutamide buserelin may stop adrenal gland produce androgen . OGX-011 may help flutamide buserelin kill tumor cell make tumor cell sensitive drug . Giving flutamide buserelin OGX-011 surgery may shrink tumor remove surgery . PURPOSE : Phase I trial study effectiveness combine hormone therapy OGX-011 radical prostatectomy treat patient prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy OGX-011 Before Radical Prostatectomy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose OGX-011 ( clusterin antisense oligonucleotide ) administer neoadjuvant hormonal therapy radical prostatectomy patient adenocarcinoma prostate . - Determine toxicity regimen patient . - Determine pharmacokinetics OGX-011 regimen administer patients.. - Assess effect regimen pathologic complete response rate patient . - Correlate plasma and/or prostate concentration OGX-011 patient response toxicity measure . OUTLINE : This dose-escalation study OGX-011 . Patients receive OGX-011 IV 2 hour day 1 , 3 , 5 , 8 , 15 , 22 , 29 ; oral flutamide three time daily 4 week ; buserelin subcutaneously day 1 . Cohorts 3-6 patient ( except 1 patient start dose ) receive escalate dos OGX-011 maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 3 2 6 patient experience dose-limiting toxicity . The recommended phase II dose dose precede MTD . Patients undergo radical prostatectomy bilateral pelvic lymphadenectomy 1 week last dose neoadjuvant therapy . Patients follow 7 day surgery 3 month . PROJECTED ACCRUAL : Approximately 25-33 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Highrisk , localize disease previously untreated Minimum 2 positive biopsy Meets least 1 follow criterion : Stage T3 Serum PSA great 10 ng/mL Gleason score 710 Gleason score 6 least 3 positive biopsy Potential candidate radical prostatectomy PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10.0 g/dL Hepatic Bilirubin normal AST ALT normal PTT normal INR normal Renal Creatinine normal Cardiovascular No significant cardiac dysfunction Other Fertile patient must use effective contraception No known hypersensitivity oligonucleotides , luteinizing hormonereleasing hormone analog , antiandrogens No evidence active uncontrolled infection No malignancy within past 5 year except adequately treat nonmelanoma skin cancer No serious illness , psychiatric disorder , medical condition would preclude study compliance No history significant neurological disorder would preclude informed consent No geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy prostate cancer Endocrine therapy No prior hormonal therapy prostate cancer Radiotherapy No prior radiotherapy prostate cancer No concurrent radiotherapy Surgery Not specify Other No concurrent heparin warfarin anticoagulation No concurrent investigational therapy No concurrent cytotoxic therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
</DOC>